Hemoglobinopathies: Clinical Trials

395 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

194 completed, 55 terminated, 51 recruiting, 35 unknown. 395 Phase 2, 94 Phase 1, 34 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2395Completed 194, Terminated 55, Recruiting 51, Unknown 35, Active not recruiting 31, Withdrawn 22, Not yet recruiting 6, Enrolling by invitation 1
Phase 194Completed 34, Active not recruiting 16, Recruiting 16, Terminated 13, Unknown 7, Withdrawn 4, Not yet recruiting 3, Enrolling by invitation 1
Phase 334Completed 19, Unknown 11, Recruiting 2, Active not recruiting 1, Terminated 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 395 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Feasibility and Acceptability of Amani
Amani - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingMassachusetts General Hospital402026-11-012026-08-07
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia
Phase 2RecruitingBiossil Inc.652026-11-012026-11-02
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease
Phase 2RecruitingMohsen Saidinejad1202026-09-102026-09-02
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease
Phase 2RecruitingSt. Jude Children's Research Hospital452026-09-102026-11-12
Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia
HGI-001 Injection - Beta Thalassemia Transfusion Dependent
Phase 2Not yet recruitingPrince of Wales Hospital, Shatin, Hong Kong62026-09-012026-07-23
Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs - Bone Marrow Failure, Hemoglobinopathies
Phase 2Not yet recruitingFred Hutchinson Cancer Center402026-09-012026-06-22
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia
Phase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)902026-07-082026-10-13
Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation
Intravenous Immunoglobulin, Dexamethasone, Mononuclear Cells - Leukemia, Lymphoma
Phase 2Not yet recruitingHematology department of the 920th hospital602026-07-032026-07-14
A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)
SNH-119014 dose 1, SNH-119014 dose 2, Placebo - Thalassemia
Phase 2RecruitingScinnoHub Pharmaceutical Co., Ltd.302026-06-162026-11-19
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant
Phase 1 / Phase 2RecruitingArkansas Children's Hospital Research Institute242026-06-082026-06-04
STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE
Plerixafor Dose Escalation - Sickle Cell Disease
Phase 1 / Phase 2Not yet recruitingHospital Israelita Albert Einstein122026-06-012026-01-14
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
hydroxycarbamide - Sickle Cell Disease, Sickle Cell Anemia in Children
Phase 1 / Phase 2RecruitingChildren's Hospital Medical Center, Cincinnati2502026-05-132026-07-16
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Phase 2RecruitingUniversity of Illinois at Chicago202026-04-082026-05-19
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Pociredir - Sickle Cell Disease
Phase 2TerminatedFulcrum Therapeutics12026-03-302026-10-28
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Alendronate Sodium - Sickle Cell Disease, Sickle Cell Anemia
Phase 2RecruitingUniversity of California, Davis302026-03-092026-07-16
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
Mitapivat - Sickle Cell Disease, Nephropathy
Phase 2WithdrawnAgios Pharmaceuticals, Inc.2026-03-012026-04-03
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
DREAM01 drug product, anti-inflammatory therapy - Sickle Cell Disease
Phase 1 / Phase 2RecruitingAssistance Publique - Hôpitaux de Paris152026-02-252026-03-04
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
25 mg/day zinc, 40 mg/day zinc - Sickle Cell Disease
Phase 2RecruitingUniversity of California, San Francisco342026-02-142026-03-13
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
Pharmacokinetic based dosage change, Pharmacokinetic dosing - Sickle Cell Disease (SCD)
Phase 2 / Phase 3RecruitingYves Pastore292026-02-032026-08-21
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Anumigilimab, Placebo - Sickle Cell Disease
Phase 2RecruitingCSL Behring632026-02-022026-11-03

Showing 20 of 395. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (293)  ·  beta-Thalassemia (87)  ·  Thalassemia (71)  ·  Vaso-Occlusive Crises (27)  ·  Anemia (24)  ·  Iron Overload (21)  ·  Anemia, Diamond-Blackfan (18)  ·  Hematologic Diseases (17)  ·  Genetic Diseases, Inborn (16)  ·  Anemia, Aplastic (13)  ·  Bone Marrow Failure Disorders (13)  ·  Acute Chest Syndrome (10)  ·  Myelodysplastic Syndromes (10)  ·  Anemia, Hemolytic (9)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (394)  ·  Hemic and Lymphatic Diseases (394)  ·  Anemia, Hemolytic, Congenital (382)  ·  Genetic Diseases, Inborn (379)  ·  Hematologic Diseases (378)  ·  Anemia, Hemolytic (377)  ·  Anemia (365)  ·  Thalassemia (67)  ·  Pathological Conditions, Signs and Symptoms (48)  ·  Nutritional and Metabolic Diseases (46)  ·  Metabolic Diseases (38)  ·  Bone Marrow Diseases (35)  ·  Immune System Diseases (30)  ·  Pathologic Processes (30)

Interventions

Hydroxyurea (44)  ·  Alemtuzumab (26)  ·  Cyclophosphamide (25)  ·  Deferasirox (22)  ·  Sirolimus (22)  ·  fludarabine (21)  ·  Busulfan (19)  ·  fludarabine phosphate (18)  ·  Whole-Body Irradiation (17)  ·  Deferoxamine (12)  ·  Mycophenolic Acid (11)  ·  Tacrolimus (10)  ·  thymoglobulin (10)  ·  Melphalan (9)  ·  Antilymphocyte Serum (8)

Sponsors

Novartis Pharmaceuticals (19)  ·  National Heart, Lung, and Blood Institute (NHLBI) (18)  ·  St. Jude Children's Research Hospital (10)  ·  Assistance Publique - Hôpitaux de Paris (8)  ·  Children's Hospital Medical Center, Cincinnati (8)  ·  UCSF Benioff Children's Hospital Oakland (8)  ·  Emory University (6)  ·  University of North Carolina, Chapel Hill (6)  ·  Ain Shams University (5)  ·  Baylor College of Medicine (5)  ·  Johns Hopkins University (5)  ·  New York Medical College (5)  ·  University of Illinois at Chicago (5)  ·  Agios Pharmaceuticals, Inc. (4)  ·  Boston University (4)

Countries

United States (265)  ·  United Kingdom (45)  ·  Italy (38)  ·  Canada (36)  ·  Lebanon (32)  ·  France (30)  ·  Turkey (Türkiye) (25)  ·  Greece (18)  ·  Thailand (18)  ·  Egypt (14)  ·  China (13)  ·  Brazil (12)  ·  Kenya (10)  ·  Nigeria (10)  ·  Germany (9)

Top investigators

Claudia Morris, MD (4)  ·  John F Tisdale, M.D. (4)  ·  Kenneth I Ataga, MD (4)  ·  Damiano Rondelli, MD (3)  ·  Mark Walters (3)  ·  Mitchell S Cairo, MD (3)  ·  Russell Ware, MD, PhD (3)  ·  Shalini Shenoy, MD (3)  ·  A O Dosunmu, M.D. (2)  ·  Ahmed F Mahmoud Hussein, MS.c (2)

Results publications

PMID 36240296, PMID 37975597, PMID 42133908, PMID 34175041, PMID 37254256, PMID 26348869, PMID 38775255, PMID 40569673, PMID 29931453, PMID 32384147, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 36860093, PMID 36975201, PMID 38866240, PMID 40010689, PMID 41026975, PMID 41809202, PMID 41871072, PMID 41954645, PMID 42224366, PMID 42549972, PMID 14550808, PMID 15592491, PMID 16990602, PMID 17233848, PMID 18026148, PMID 18192510, PMID 18500373, PMID 18550258, PMID 20007560, PMID 20421452, PMID 20955402, PMID 21173101, PMID 21275961, PMID 21364138, PMID 21393329, PMID 21477202, PMID 21527519, PMID 21700776, PMID 21742281, PMID 21900080, PMID 22129980, PMID 22251482, PMID 22571408, PMID 2265118, PMID 22875626, PMID 22887019

NIH funding

2018 (5), 2014 (4), 2023 (4), U01HL065238 (4), 2017 (3), 2019 (3), 2016 (2), 2025 (2), K24AT009893 (2), U24CA076518 (2), U54HL070587 (2), 1OT2HL154815 (1), 1UG3AT011265-01 (1), 2004 (1), 2015 (1)